Collaborations

Agreement signed to distribute BrachySil throughout the People's Republic of China

Published in Drug Week, November 25th, 2005

Beijing Med-Pharm Corp. (BJGP.PK) and pSivida Limited (PSD, PSDV, PSI) announced that they have signed a licensing agreement for the clinical development, marketing, and distribution of pSivida's lead product, BrachySil, in the People's Republic of China.

Under the terms of the license, pSivida will manufacture BrachySil and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing, and distribution in China.

Beijing Med-Pharm is a U.S.-based company with Chinese subsidiaries that offers an end-to-end solution to Western pharmaceutical companies that wish to sell their products into the Chinese...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry